A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects.

Liraglutide, a glucagon-like peptide 1 receptor agonist, is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. The original liraglutide products are costly, which limits patient access to this therapeutic treatment. Herein, a biosimilar was developed that is highly similar to the reference drug in molecular structure and bioactivity, and is expected to have similar pharmacokinetic (PK) and safety profiles in clinical studies.

Corrosion behaviors of amorphous and nanocrystalline Fe-based alloys in NaCl solution.

Amorphous Fe(73.5)Si(13.5)B9Nb3Cu1 alloy was prepared by the chill block melt-spinning process and nanocrystalline Fe(73.